Bevacizumab in the treatment of metastatic colorectal cancer: the RFOM in the experience of the A.O. University of Siena

Authors

  • Davide Paoletti Azienda Ospedaliera Universitaria Senese, Settore Governo Clinico della Spesa Farmaceutica, Siena - Italy
  • Silvano Giorgi Azienda Ospedaliera Universitaria Senese, Settore Governo Clinico della Spesa Farmaceutica, Siena - Italy

DOI:

https://doi.org/10.33393/grhta.2015.326

Downloads

Download data is not yet available.

Downloads

Published

2015-03-17

How to Cite

Paoletti, D., & Giorgi, S. (2015). Bevacizumab in the treatment of metastatic colorectal cancer: the RFOM in the experience of the A.O. University of Siena. Global and Regional Health Technology Assessment, 2(1), 61–62. https://doi.org/10.33393/grhta.2015.326

Issue

Vol. 2 No. 1 (2015): January-April 2015

Section

Correspondence

License

Copyright (c) 2015 The authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors contributing to Global & Regional Health Technology Assessment agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.

 

Metrics

Crossref
Scopus
Google Scholar
Europe PMC